Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPO906 in advanced ovarian, fallopian, or peritoneal cancer
NCT00035100Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2001
- Primary completion
- Jun 2003
- Modality
- Covalent Small Molecules, RNA-Targeting Small Molecules, Classical Binding Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of patupilone in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Novartis. Started Sep 2001; status: completed.
02
Drugs
patupilone
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00035100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00035100.